Related Experiment Video
Updated: Jun 23, 2025

12:16
A Syngeneic Mouse B-Cell Lymphoma Model for Pre-Clinical Evaluation of CD19 CAR T Cells
Published on: October 16, 2018
14.7K
CD19 CAR T cells for multiple sclerosis: Forging further into the new frontier
Alexander W Rankin1, Nirali N Shah1
1Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Med (New York, N.Y.)
|June 15, 2024
Abstract
None:
The efficacy of CD19 chimeric antigen receptor (CAR) T cells in B cell malignancies has generated recent interest in their application to other B cell-related pathologies, such as autoimmune diseases. Fischbach et al.1 report on the use of CD19 CAR T cells in two patients with progressive multiple sclerosis, demonstrating feasibility and safety for the first time in this disease process.

